scholarly journals Commentary: Reflections on G. M. Lower and colleagues’ 1979 study associating slow acetylator phenotype with urinary bladder cancer: meta-analysis, historical refinements of the hypothesis, and lessons learned

2007 ◽  
Vol 36 (1) ◽  
pp. 23-28 ◽  
Author(s):  
Nathaniel Rothman ◽  
Montserrat Garcia-Closas ◽  
David W Hein
2017 ◽  
Vol 2017 ◽  
pp. 1-6 ◽  
Author(s):  
Xiang-Yu Meng ◽  
Ming-Jun Shi ◽  
Jia-Feng Chen ◽  
Yi Liao ◽  
Bang-Wang Hu ◽  
...  

Background. A possible association between the TACC3 rs798766 polymorphism and urinary bladder cancer risk has been indicated in published literature. We performed this meta-analysis as a synthesis of all relevant data to summarize currently available evidence and to provide estimation with increased precision. Methods. EMBASE, PubMed, Google Scholar, and Wanfang Data were searched. “rs798766” and “urinary bladder cancer” were used as the search terms. A total of 6 eligible studies were identified, in which 8194 cases and 50,165 controls were investigated. Meta-analysis was performed using extracted data. Subgroup analysis by ethnicity was also performed. Population attributable risk (PAR) was calculated. Results. We found a significant association between rs798766[T] and increased risk of bladder cancer, allelic[T] OR=1.27, 95%CI=1.20–1.33. Subgroup analysis by ethnicity revealed similar results, allelic[T] OR=1.24, 95%CI=1.17–1.32 in Caucasian subjects and allelic[T] OR=1.33, 95%CI=1.21–1.46 in Asian subjects. PAR based on pooled allelic ORs and the frequency of the risk allele in control subjects was 4.63% in the overall population and 3.92% in Asians and 4.36% in Caucasians. Conclusion. rs798766 is associated with increased risk of bladder cancer, and no ethnic difference was found.


1997 ◽  
Vol 80 (1) ◽  
pp. 151-152 ◽  
Author(s):  
M.T. ESPIN JAIME ◽  
J.M. MORAN PENCO ◽  
J.A. GARCIA AGUNDEZ ◽  
M.J. CABALLERO LOSCOS ◽  
S. SANJUAN RODRIGUEZ ◽  
...  

2012 ◽  
Vol 81 (9) ◽  
pp. 2411-2416 ◽  
Author(s):  
Yu-Yu Lu ◽  
Jin-Hua Chen ◽  
Ji-An Liang ◽  
Hsin-Yi Wang ◽  
Cheng-Chieh Lin ◽  
...  

Tumor Biology ◽  
2015 ◽  
Vol 36 (5) ◽  
pp. 3209-3214 ◽  
Author(s):  
Huojun Zhang ◽  
Wei Xing ◽  
Qinqin Kang ◽  
Chao Chen ◽  
Linhui Wang ◽  
...  

2021 ◽  
Vol 8 ◽  
Author(s):  
Zhihua Geng ◽  
Qing Geng

A systematic search of the PubMed, Cochrane, Embase, and Web of Science databases was conducted to investigate the risk of urinary bladder cancer (BC) in patients with inflammatory bowel disease (IBD). We identified 168 articles, of which 11 met the inclusion and exclusion criteria. Our analysis included 165,176 patients with IBD, 491 of whom had BC. Overall, the pooled standardized incidence ratio (SIR) was 0.99 (95% CI: 0.87–1.12; I2 = 0%). Further subgroup analysis showed that BC risk was neither statistically higher for Crohn's disease (CD) (SIR: 1.19; 95% CI: 0.94–1.44; I2 = 0%) nor for patients with ulcerative colitis (UC) (SIR: 0.92; 95% CI: 0.77–1.06; I2 = 0%). In the analysis of two case-control studies providing data on BC in UC and CD combined, IBD patients seemed to have a higher risk of BC than non-IBD patients (relative risk: 1.25; 95% CI: 0.77–2.03; I2 = 37.5%). Although the overall risk of BC was not significantly increased among patients with IBD, there was a weak trend for the risk to be elevated in CD patients, indicating marginal significance. These findings may primarily be explained by the opposite effects of smoking on CD and UC as well as the immunosuppressive drugs these patients often take.


Meta Gene ◽  
2021 ◽  
pp. 100848
Author(s):  
Prashant Tripathi ◽  
Rajender Singh ◽  
Alok Raghav ◽  
Satya Narayan Sankhwar ◽  
Sandeep Kumar Bansal ◽  
...  

2005 ◽  
Vol 173 (4S) ◽  
pp. 211-211
Author(s):  
Loleta D. Harris ◽  
Tomasz Tuziak ◽  
Jorge De Lo Cerda ◽  
Anita L. Sabichi ◽  
Ying Yang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document